The engagement of Epstein-Barr virus (EBV)-induced protein ligands in cd T-cell-mediated anti-EBV immunity, especially in EBV-associated B-cell malignancies, has not been fully elucidated. Previously we reported the overexpression of human MutS homologue 2 (hMSH2), a stress-inducible protein ligand for human cd T-cells, on EBV-transformed B lymphoblastic cell lines (B-LCLs). In this study, we first generated EBV-transformed B-LCLs from peripheral blood mononuclear cells of healthy volunteers with B95-8 cellular supernatant and cyclosporine A. Secondly, we demonstrated the significantly elevated cell surface protein expression and mRNA transcription of hMSH2 in EBV-transformed B-LCLs, 3D5 and EBV-positive B lymphoma cell line Daudi and Raji. Thirdly, hMSH2-mediated recognition of EBV-transformed B malignant cells by human cd T-cells was confirmed by specific antibody blocking and siRNA interference. Both TCRcd and NKG2D participated in hMSH2-mediated recognition of EBV-transformed B malignant cells. Furthermore, hMSH3 and hMSH6, the companion proteins of hMSH2, along with CD98, were found overexpressed on the surface of EBV-transformed malignant B-cells. We concluded that the induced overexpression of hMSH proteins might serve as early alerting biomarkers emerged in EBV-related B-cell malignances or as potential targets for establishing cd T-cell-based therapeutic immunotherapies towards EBV infection.
Introduction
cd T-cells are a special subset of T lymphocytes. They are characterized by their ability to recognize antigens in an MHC-unrestricted pattern and occupy a unique status in innate anti-tumour/infection immunity. 1 Epstein-Barr virus (EBV) was the first virus found to cause human cancers, and is associated with a wide range of cancers originating from B lymphocytes, epithelial cells and mesenchymal cells. [2] [3] [4] The development of EBV-related neoplasm is determined by environmental factors and individual genetic susceptibility to viral infection associated with genetically prone immune deregulation. 5 Primary immune-deficiency also causes genetic susceptibility to viral infection. 3 EBV-driven B-cell or T/NK lymphoproliferative disorders are common manifestations in EBV-associated oncogenesis. [6] [7] [8] Epstein-Barr virus immunity is primarily mediated by CD8 + T-cells. 9 cd T-cells have been shown to contribute to EBV-associated immune responses as well. [10] [11] [12] EBVinduced protein ligands such as HSP60, HSP70 and HSP90 for human cd T-cells have been suggested as possible biomarkers for innovative therapeutic tumour strategies. [13] [14] [15] However, the engagement of EBV-induced protein ligands in cd T-cell-mediated anti-EBV immunity especially in anti-EBV-associated B-cell malignancies remains to be further elucidated.
Human MutS homologue 2 (hMSH2) is a critical element of DNA mismatch repair protein family. It has been identified as a tumour-associated endogenous protein ligand recognized by cd T-cells in our previous study. 12 Ectopically expressed hMSH2 on epithelial tumour cell lines could bind to T-cell receptor (TCR) or NK group2 D (NKG2D) to promote the proliferation and the cytotoxicity of cd T-cells towards epithelial tumour targets. 12, 16 The ectopic expression of hMSH2 could be induced by oxidative stress with interleukin-18 induction via the p38 mitogen-activated protein kinase (MAPK) and c-Jun N-terminal kinase (JNK) signalling pathways. 17 The current work was built on the bases of our previous studies to elucidate the recognition of hMSH2-overexpressed B lymphoblastic cells by human cd T-cells and the induction of its companion proteins accompanied by EBV transformation. Firstly, we generated EBV-transformed B lymphoblastic cell lines (B-LCL) by infecting peripheral blood mononuclear cells (PBMCs) with EBV to determine the effect of EBV transformation on hMSH2 gene expression and the recognition of EBV-induced ectopic hMSH2 overexpression by human cd T-cells. The change of its companion proteins hMSH3 and hMSH6 was also analysed during this process. Overexpression of hMSH2, hMSH3 and hMSH6 was observed in newly generated B-LCLs, 3D5 and EBV-positive B-LCL Daudi and Raji. The ectopic membrane hMSH2-mediated recognition and cytolysis of malignant B-cells by cd T-cells were confirmed to occur with TCRcd and NKG2D dual pathway. Our results suggest that the ectopic membraneexpressed hMSH proteins might be promising early emerging biomarkers for EBV-related B-cell malignances or immune-targets for cd T-cell-based anti-EBV therapy.
Materials and methods

Cell lines and medium
B95-8 (macaque B lymphoma), Daudi and Raji (EBVpositive human B lymphoma) cell lines were purchased from the cell centre of the Institute of Basic Medical Sciences of Chinese Medical Academy. 3D5, a staphylococcus-activated EBV-transformed B-LCL, was a kind gift from Professor Li-ping Zhu (Department of Immunology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and School of Peking Union Medical College). Both suspension cell lines were maintained with complete RPMI-1640 containing 10% fetal bovine serum (FBS).
Generation of EBV-transformed B-LCLs
Peripheral blood mononuclear cells (approximately 8 9 10 6 cells) separated from healthy adult donors were suspended in 2Á4 ml RPMI-1640 medium (15% FBS) followed by addition of 0Á4 ml Cyclosporine A (Novartis Pharma AG, Switzerland), 0Á5% (w/v) phytohaemagglutinin (Sigma, Sigma-Aldrich, St. Louis, MO,USA) and 1Á2 ml B95 cell culture supernatant. After being mixed completely, the cells were planted in 24-well plates (1 ml/well) and incubated in an atmosphere of 37°, 5% CO 2 . The growth of B lymphoblastic clumps was observed with an inverted microscope 3-6 days after transformation. The medium was supplemented 3-4 days later (depending on the growth state of the cells). Transformed B-LCLs could be frozen at a concentration of 3-6 9 10 6 cells/ml or subcultivated for sequent experiments.
In vitro cd T-cell amplification and B-cell separation
Peripheral blood mononuclear cells separated from healthy adult donors were diluted to 3-5 9 10 6 cells/ml and planted in 24-well plates (1 ml/well) that were preimmobilized with anti-pan-TCRcd McAb (10 ll/well; Immunotech, Marseille, France) at 37°, 5% CO 2 . The amplified cd T-cells were collected on days 10-14, the purity and the phenotype of which were analysed with FCM. Peripheral B-cells were separated with human B-cell isolation kit II (Miltenyi Biotech, Bergisch Gladbach, Germany) according to the manufacturer's specifications. Separated peripheral B-cells were stained with PE-labelled CD19 McAb (Miltenyi Biotech) before being used in sequent experiments.
mRNA expression of hMSH2 in EBV-transformed B malignant cells
Total RNA of EBV-transformed B-LCLs, 3D5, Daudi, Raji, in vitro-expanded cd T-cells and sorted peripheral B-cells (1-2 9 10 7 cells) were isolated using TRIzol reagent (Promega, Madison, WI). cDNA was synthesized using oligo(dT) (Promega) and Moloney murine leukaemia virus reverse transcriptase (Promega) in reverse transcription (RT) reactions. Quantitative (q) real-time polymerase chain reaction (PCR) was performed in a volume of 20 ll containing cDNA template, oligonucleotide primers and SYBR Green PCR master mix (Applied Biosystems, Warrington, UK) using a 7500 real-time PCR system (Applied Biosystems). Primers for amplification of hMSH2 and b-actin (endogenous control) genes were listed in Table 1 . The cycling conditions were 95°for 10 min, 40 cycles at 95°for 15 seconds and 55°for 45 seconds. The data were analysed using the SEQUENCE DETECTOR Version 1Á2 analysis software (Applied Biosystems). 5 cells/ml) were planted on glass clips overnight before being treated with 4% PFA or ice-cold methanol. The cells were blocked with 0Á5% bovine serum albumin, and incubated with anti-hMSH2 PcAb (N-20; Santa Cruz Biotechnology) or isotype-matched rabbit IgG (Santa Cruz Biotechnology) at 4°for 1 hr before reacting with FITC-labelled goat anti-rabbit secondary Ab (Jackson Laboratory). The nuclei of the examined cells were stained with 4',6-diamidino-2-phenylindole (DAPI). Bcells were additionally labelled with anti-CD19 PE (Miltenyi Biotech). The surface and subcellular expressions of hMSH2 were analysed with Leica DMIRE2 inverted microscope image system (oil, 40 9; numeral, 1Á25).
Cell cytotoxicity and antibody blockade cytotoxicity assay
The cytotoxicity of cd T-cells against target EBV-transformed B-LCLs, 3D5, EBV-positive B lymphoma cells The cytotoxicity of cd T-cells was calculated by the following formula:
hMSH2 gene knockdown with specific siRNAs in 3D5 cells
Specific siRNA duplexes targeting at hMSH2 gene (NM 000251Á1) were synthesized and listed in Tables 1 and 2 . siRNA I, siRNA II or Stealth TM RNAi negative control med GC (Invitrogen) were invert transfected into 3D5 cells (final concentration 10 nM) following the manufacturer's instructions. The BLOCK-iT TM Fluorescent Red Oligo (Invitrogen) was used as a parallel transfection control to evaluate specific siRNA transfection efficiency. The mixture was incubated in a 5% CO 2 incubator at 37°and medium was changed 6 hr after transfection. The cells were collected to analyse the siRNA interference efficiency and the killing ability of effector cells on targets 48 hr or 60 hr after transfection with Western blot, FCM and confocal microscopy.
Statistics
Student's t-test or one-way ANOVA was used to calculate the difference between different experimental groups. A value of P ≤ 0Á05 was considered significant.
Results
Generation of EBV-transformed B-LCL
As shown in Fig. 1 , EBV-transformed PBMCs formed cell clumps at day 3 (labelled with white arrow). The nontransformed PBMCs died and gradually disappeared. Successfully transformed B lymphocytes developed to B-LCLs at day 40. These EBV-transformed B-LCLs could be subcultivated for generations. EBV transformation induced significant surface expression of hMSH2 in B-LCLs FCM analyses revealed significant overexpression of ectopic membrane hMSH2 on both 3D5 and newly generated B-LCLs when compared with isolated peripheral B-cells and human cd T-cells (Fig. 2) . B lymphoma cell lines Daudi and Raji also displayed different extents of surface hMSH2 expression (17Á5% and 20Á6%, respectively; Fig. 2 ). The surface expression of hMSH2 on each EBV-positive B-malignant cell line was also confirmed by IIF assay with laser confocal microscopy ( Fig. 3b,c) . The results suggested that EBV infection induces the ectopic surface expression of hMSH2 on B lymphocytes. Subcellular location analysis with IIF assay showed a dense accumulation of hMSH2 in Daudi and Raji cells' nuclei, implying an active hMSH2 expression in these EBV-positive B lymphoma cell lines.
To explore the activation of hMSH2 gene transcription in EBV-transformed B malignant cell lines, relative mRNA expression ratios of hMSH2 in newly generated EBV-transformed B-LCLs, 3D5, Daudi, Raji and in vitroexpanded human cd T-cells were analysed with qRT-PCR and compared with isolated peripheral B-cells. The relative mRNA expression in newly generated B-LCLs was approximately 3Á3 times that of peripheral B-cells, while in staphylococcus-activated EBV-transformed 3D5 cell line, it was increased 325-fold (Fig. 3a) . EBV-positive B lymphoma cell lines Daudi and Raji also displayed relatively high level hMSH2 mRNA expression (Fig. 3a) . These results suggested that EBV transformation may upregulate the gene transcription of hMSH2 in malignant B-cells. Combined infection with staphylococcus may further activate hMSH2 gene transcription.
Surface-expressed hMSH2 engaged in cd T-cellmediated cytolysis of EBV-transformed B-LCLs
To demonstrate the role of EBV transformation-induced hMSH2 in cd T-cell-mediated killing ability in B-cell malignances, we first assessed the cytotoxicity of antipan-TCRcd McAb amplified cd T-cells towards newly established EBV-immortalized B-LCLs, 3D5, EBV-positive B lymphoma cell lines Daudi and Raji, isolated human B-cells were set as normal control. We found that cd T-cells displayed remarkable cytotoxicity against newly generated B-LCLs, 3D5 and Daudi cells at various E : T ratios, but had very poor killing ability on Raji and isolated peripherial B-cells (Fig. 4a) . The cytolysis of pre-EBV-transformed and post-EBV-transformed peripheral B-cells by cd T-cells amplified from two different healthy donors showed statistically significant differences at various E : T ratios, implying EBV transformation upregulates the surface expression of some cd T-cells' ligands to enhance the cytolysis of these EBV-infected B malignant cells by effector cd T-cells (Fig. 4b) . The engagement of EBV-induced cell surface-expressed hMSH2 in cd T-cell-mediated recognition of EBV-transformed B-LCLs was subsequently confirmed by specific anti-hMSH2 PcAb (N-20) blockade cytotoxicity assay in newly generated B-LCLs and 3D5 (Fig. 4c) . At E : T ratio of 10 : 1, 5 : 1 and 2Á5 : 1, both target cell lines displayed decreased cytolysis by effector cd T-cells after specific anti-hMSH2 antibody blocking. Our results presented direct evidences for the engagement of surface overexpressed hMSH2 in cd T-cell-mediated cytotoxicity against EBV-transformed malignant B-cells.
hMSH2 gene knockdown significantly reduced the cytolysis of 3D5 by cdT-cells
To further validate the recognition of surface-expressed hMSH2 on EBV-transformed B-LCLs by human cd T-cells, specific siRNAs were introduced into 3D5 cells to knockdown hMSH2 gene expression. mRNA and protein expression of hMSH2 in the specific siRNAs interfering groups were significantly downregulated compared with mock controls 48 and 60 hr after siRNA I or siRNA II transfection (Fig. 5a ). The cytotoxicity assay showed that the cytotoxicity efficiencies of effector cd T-cells against siRNA I or siRNA II interfering 3D5 groups were significantly lower than those of mock control groups, indicating that the reduced surface expression of hMSH2 by gene knockdown downregulated the cytolysis of 3D5 by effector cd T-cells. These data further confirmed the inducible ectopic cell surface expression of hMSH2 promoted the recognition and cytotoxicity of cd T-cells towards EBV-transformed malignant B-cell targets, which was consistent with the results achieved by specific anti-hMSH2 antibody blocking in both newly established B-LCLs and 3D5 cells (Fig. 5b) . (149810), we confirmed that both TCRcd and NKG2D were involved in the cell surface hMSH2-mediated cd T-cell cytotoxicity against 3D5, indicating that a dual recognition mechanism by cd T-cells also existed in hMSH2-mediated anti-EBV-transformed B-cell malignance (Fig. 5c ).
EBV transformation induced ectopic surface expression of hMSH3 and hMSH6 on B-LCLs
Because hMSH2 must combine with its companion proteins hMSH3 or hMSH6 to form complexes to fulfill its normal function in the nucleus, we assessed the surface ectopic expression of hMSH3 and hMSH6 on EBV-transformed B-LCLs, 3D5, and EBV-positive B lymphoma cell lines Daudi and Raji, isolated peripheral B-cells were set as control. FCM data showed that the four examined EBV-infected malignant B-cell lines expressed a higher level of ectopic hMSH3 and hMSH6 on their cell surface; while on isolated peripheral B-cells, expression of these two molecules was relatively low (8Á22% and 1Á05%, respectively; Fig. 6a ). Surface expressions of CD19, CD25 and CD98 were also analysed in EBV-transformed B-LCLs and 3D5 (Fig. 6b) . In EBV-transformed B-LCLs, CD19 expression ranged from 41Á2% to 97Á0%, while in 3D5 was up to 82%. 3D5 cells also displayed high level expressions of both CD25 and CD98 molecules. Interestingly, one strain of EBV-transformed B-cells could be divided into two subsets: one subset (subset A) was CD19 (Fig. 6 ). Both subsets displayed high expression of hMSH2 on their cell surface. The biological difference between these two subsets needs to be further explored. 
Discussion
The EBV belongs to the Herpes virus family. EBV infection is associated with a series of tumours, such as nasopharyngeal carcinoma, 18, 19 Burkett lymphoma, stomach cancer and non-Hodgkin's lymphoma, [20] [21] [22] and certain autoimmune diseases in genetically sensitive individuals. 23, 24 Preferable proliferation of cd T-cells has been observed in urgent or chronic EBV infections. 13, 14 Some protein ligands for human cd T-cells, such as HSP60, HSP90 and ULBPs, were found to be unregulated in virus-infected cells. 11, 25, 26 These overexpressed membrane ligands could enhance the recognition and cytotoxicity of cd T-cells towards malignant host cells. Previously, we have reported the overexpressed ectopic hMSH2 on epithelial tumour cell surface as a stress-inducible ligand for human cd T-cells, by promoting their cytotoxicity against tumour targets via both TCRcd and NKG2D. 12 We also described the inducible expression of hMSH2 on BLCLs by EBV transformation, and the involvement of which in cd T-cell mediated anti-B-LCLs immunity.
The current work was based on this to further explore the role of hMSH2 in cd T-cell-mediated innate immune responses against EBV-induced B-cell malignances. 27 In vitro, rested B-cells infected by EBV could be activated and transformed into a non-limited proliferative lymphoid blast cell line. In this study, EBV-transformed B malignant cell models were generated to explore the inducible ectopic membrane expression of hMSH2, hMSH3 and hMSH6 on EBV-transformed B malignant cells as well as the recognition mechanisms of hMSH2 by cd T-cells in anti-EBV immunity. The ectopic cell surface hMSH2 overexpressions were observed on newly generated EBV-transformed B-LCLs, 3D5 (a staphylococcusactivated EBV-transformed LCL), and EBV-positive B lymphoma cell line Daudi and Raji, yet were barely expressed on isolated peripheral B-cells and in vitroexpanded human cd T-cells, suggesting the ectopic membrane expression of hMSH2 could be induced by EBV infection in human peripheral B-cells. Furthermore, the remarkably elevated mRNA levels of hMSH2 in EBV-transformed B-LCLs, 3D5 and EBV-positive Daudi and Raji cells indicated that EBV transformation efficiently activated hMSH2 gene expression in these malignant B-cell lines. This response might be a specific stress-inducible reaction of host cells to EBV pathogens.
The significantly increased killing ability of cd T-cells towards EBV-transformed B-cells should be closely related to the upregulated expression of ligands recognized by cd T-cells induced by EBV infection. This is also part of the innate immune-defense mechanism underlying the process of the cd T-cell battle against the invasion of exogenous antigens. The findings achieved by specific antibody blockage and hMSH2 gene knockdown with siRNA interference demonstrated that the surfaceexpressed hMSH2 played a vital role in the clearance of EBV-infected B lymphocytes by cd T-cells. Similar to the mechanisms in epithelial tumours, the recognition of hMSH2-overexpressed B-LCLs by human cd T-cells was currently confirmed through both TCRcd and NKG2D. 12 The performance of hMSH2 in innate anti-EBV immunity not only suggests that it is a biological stress-inducible molecule, but also reflects that the ectopically overexpressed endogenous antigen-related pre-alarming mechanism might have unique significance in cd T-cellmediated anti-B-cell malignance immunity. These findings may not only provide promising solutions for hMSH2 as a novel biomarker in EBV-related B lymphoma genesis, but also serve as a potential molecular target for the establishment of cd T-cell-based immune therapeutic clinical strategies against virus infection. 25, 26, 28, 29 high . Both subsets expressed a high level expression of ectopic membrane hMSH2 proteins. CD25, the interleukin-2 receptor alpha chain, is one of the activation biomarkers for human Bcells. 30 It has been reported serving as a negative growth regulator, a novel marker and potential drug target in chronic myeloid leukaemia. 31 In 3D5 cells, the expression of CD25 significantly increased; whereas in newly generated EBV-transformed B-LCLs, the expression of which was of the same level with normal PBMC controls. The difference in CD25 expression between 3D5 cells and newly EBV-transformed B-LCLs may be caused by staphylococcus infection.
CD98 is a heterodimeric transmembrane protein that has been reported expressed on proliferating lymphocytes and fast-growing cells, which can promote acute myeloid leukaemia initiation and growth. 32, 33 The uncommonly high level of CD98 expression on both subsets of EBV immortalized B-LCLs and 3D5 suggested the high odds of tumorigenesis risk caused by EBV infection. 34 The role of ectopic surface-expressed hMSH3, hMSH6 and CD98 in hMSH2-mediated anti-EBV infection and anti-B-cell malignance immunity by cd T-cells remain to be further explored.
